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Abstract: Respiratory muscle weakness occurs due to dystrophin deficiency in Duchenne muscular 
dystrophy (DMD). The mdx mouse model of DMD shows evidence of impaired respiratory muscle 
performance with attendant inflammation and oxidative stress. We examined the effects of N-
acetylcysteine (NAC) supplementation on respiratory system performance in mdx mice. Eight-
week-old male wild type (n = 10) and mdx (n = 20) mice were studied; a subset of mdx (n = 10) received 
1% NAC in the drinking water for 14 days. We assessed breathing, diaphragm, and external 
intercostal electromyogram (EMG) activities and inspiratory pressure during ventilatory and non-
ventilatory behaviours. Diaphragm muscle structure and function, cytokine concentrations, 
glutathione status, and mRNA expression were determined. Diaphragm force-generating capacity 
was impaired in mdx compared with wild type. Diaphragm muscle remodelling was observed in 
mdx, characterized by increased muscle fibrosis, immune cell infiltration, and central 
myonucleation. NAC supplementation rescued mdx diaphragm function. Collagen content and 
immune cell infiltration were decreased in mdx + NAC compared with mdx diaphragms. The 
cytokines IL-1β, IL-6 and KC/GRO were increased in mdx plasma and diaphragm compared with 
wild type; NAC decreased systemic IL-1β and KC/GRO concentrations in mdx mice. We reveal that 
NAC treatment improved mdx diaphragm force-generating capacity associated with beneficial anti-
inflammatory and anti-fibrotic effects. These data support the potential use of NAC as an adjunctive 
therapy in human dystrophinopathies. 




Skeletal muscle weakness is a major feature of Duchenne muscular dystrophy (DMD) due to a 
deficiency in the protein dystrophin [1]. In healthy muscle, dystrophin has a structural role in 
supporting muscle fibres during repeated cycles of muscle contraction, acting to limit the mechanical 
stress applied to muscle fibres [2,3]. In the absence of dystrophin, such as in DMD, skeletal muscle 
fibres have increased fragility, resulting in fibre damage. Common pathological features of 
dystrophic muscle include myonecrosis, inflammation, and oxidative stress [4,5]. Due to profound 
muscle weakness and damage, children with DMD have difficulty with ambulation in their early 
years, necessitating assistive devices. 
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Respiratory system morbidity occurs in DMD due to weakness of the respiratory musculature 
[6], the end effectors of breathing. Respiratory function is compromised in boys with DMD, with 
reductions in forced vital capacity [7,8] and impaired inspiratory muscle strength [6,9], evident from 
a young age. Impaired respiratory function is most prominent during sleep, evidenced by an 
increased risk of sleep disordered breathing in children with DMD [10]. Many patients require 
ventilatory support during sleep to maintain blood gas homeostasis. Cough and airway clearance 
manoeuvres are compromised in DMD due to reduced respiratory muscle strength, such that patients 
are more susceptible to aspiration pneumonia [11]. Therapies aimed at improving respiratory muscle 
strength in DMD are necessary and attractive, in order to maintain adequate ventilation and prevent 
respiratory failure, a leading cause of mortality in DMD, notwithstanding recent advances in the 
respiratory support of DMD boys. 
Studies of the respiratory system in the mdx mouse, a preclinical model of DMD, have 
documented profound diaphragm muscle weakness and structural remodelling from a young age as 
a consequence of dystrophin deficiency [12–16]. Inflammatory markers such as immune cell 
infiltration and cytokine concentrations are increased in mdx diaphragm, as well as the abundance of 
collagen deposits [17]. Moreover, indices of oxidative stress including lipid peroxidation and 
superoxide levels are elevated in mdx diaphragm compared with control muscle [18]. Inflammation 
and high levels of reactive oxygen species (ROS) can culminate in skeletal muscle damage leading to 
poor physiological performance [19]. Oxidative stress is a recognized feature of respiratory disorders 
including DMD. Targeting oxidative stress within muscle by reducing the bioavailability of ROS or 
boosting endogenous antioxidant stores are attractive adjunctive therapies, particularly in conditions 
where redox imbalance presents and contributes to muscle pathology [20,21]. We have previously 
demonstrated that administration of a superoxide scavenger (Tempol) to mdx mice for two weeks 
restores metabolic enzyme activities and improves diaphragm muscle force-generating capacity [22]. 
It has been shown by others that Tempol supplementation reduces myonecrosis and inflammation in 
the diaphragm and biceps brachii muscles of mdx mice [23] 
N-acetylcysteine (NAC) is a dietary antioxidant and precursor to glutathione, an endogenous 
antioxidant, safe for use in humans. Interestingly, NAC is a mucolytic agent and is commonly used 
in patients with cystic fibrosis and chronic obstructive pulmonary disease. Previous studies from our 
group have demonstrated beneficial effects of NAC supplementation on respiratory muscle function 
in animal models of respiratory disease [24–26]. Studies utilising NAC as a potential therapeutic for 
dystrophic disease have yielded promising results. Pinniger et al. (2017) reported improved 
normalized grip strength and extensor digitorum longus (EDL) force in mdx mice supplemented with 
2% NAC in the drinking water for 6 weeks [27]. In a separate study, intraperitoneal injections of NAC 
in 14 day old mdx mice for 14 days reduced tumour necrosis factor-α (TNF-α) and lipid peroxidation 
levels in mdx diaphragm [28]. Terrill et al. (2012) reported that NAC administered in the drinking 
water (1% NAC for 6 weeks or 4% NAC for one week) prevented exercise-induced myonecrosis in 
quadriceps muscle of mdx mice [29]. Studies by Whitehead et al. (2008) determined that 1% NAC in 
the drinking water for 6 weeks reduced the concentration of ROS and decreased damage in EDL 
muscle of mdx mice [30]. Collectively, these studies support the use of NAC to target muscle damage 
mediated by oxidative stress in mdx mice, but no studies to date have assessed the efficacy of NAC 
in ameliorating respiratory system deficits in mdx mice. 
In the current study, we set out to perform a broad and thorough assessment of the effects of 
NAC supplementation on respiratory system performance in young (8-week-old), male mdx mice. 
Six-week-old mdx mice were treated with 1% NAC in the drinking water for 14 days. We 
hypothesized that NAC would have beneficial effects on dystrophic respiratory muscle, leading to 
preserved respiratory system performance. 
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2. Materials and Methods 
2.1. Ethical Approval 
Procedures on live animals were performed under licence in accordance with Irish and 
European directive 2010/63/EU following ethical approval by University College Cork (AEEC no. 
2013/035). Experiments were carried out in accordance with guidelines laid down by University 
College Cork’s Animal Welfare Body, and conform to the principles and regulations described by 
[31]. 
2.2. Experimental Animals and N-acetylcysteine (NAC) Treatment 
Male wild type (WT; C57BL/10ScSnJ; n = 10) and mdx (C57BL/10ScSn-Dmdmdx/J; n = 20) mice 
were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and were housed at University 
College Cork’s animal facility. Animals were housed conventionally in temperature- and humidity-
controlled rooms, operating on a 12 h light:12 h dark cycle with food and water available ad libitum. 
Mice were assigned to three different experimental groups: wild type, mdx and mdx + NAC. The mdx 
+ NAC group received 1% N-acetylcysteine (Sigma-Aldrich, Wicklow, Ireland) in the drinking water 
for 14 days, beginning at six weeks of age. Drinking water containing NAC was pH matched to 
control water (pH 8). Mice were studied at eight weeks of age. We performed a thorough assessment 
of respiratory performance, with measurements of breathing and ventilatory capacity in response to 
chemoactivation, recordings of thoracic inspiratory pressure and respiratory muscle 
electromyography (EMG) in vivo and respiratory muscle function tests ex vivo. Diaphragm muscle 
tissue was collected for structural analysis using histological and immunofluorescence techniques. 
Diaphragm glutathione status and mRNA expression were examined. Cytokine concentrations were 
determined in diaphragm and plasma samples. 
2.3. Whole-Body Plethysmography 
Whole-body plethysmography was used to assess respiratory flow in unrestrained, 
unanaesthetized mice. Mice were introduced into plethysmograph chambers (Model PLY4211; 
volume 600 mL, Buxco Research Systems, Wilmington, NC, USA) and were allowed an acclimation 
period typically lasting 40–60 min, with room air passing through each chamber (1L.min−1). 
Experimental protocol: Following acclimation, during confirmed periods of quiet rest, a 20-min 
baseline recording was performed in normoxia. This was followed by central and peripheral 
chemoreceptor stimulation with hypercapnic-hypoxia (10% O2 & 6% CO2) for 5 min, to examine 
maximum chemoactivated breathing. Respiratory parameters including respiratory frequency (fR), 
tidal volume (VT) and minute ventilation (VE) were recorded on a breath-by-breath basis for analysis 
offline. 
Data analysis: Baseline normoxic ventilation was determined as an average of the baseline 
period. For hypercapnic-hypoxia, ventilatory measurements were taken during the final (5th) minute 
of the challenge. VT and VE, were normalized for body mass (g). 
2.4. Diaphragm and External Intercostal EMG and Oesophageal Pressure Recordings 
Mice were anaesthetized with 5% isoflurane in 60% O2 (balance N2) followed by urethane (1.7 
g.kg−1 i.p.). Wild type (n = 10), mdx (n = 10) and mdx + NAC (n = 10) mice were then placed in the 
supine position and were gradually weaned from the isoflurane. Body temperature was maintained 
at 37 °C via a rectal probe and thermostatically-controlled heating blanket (Harvard Apparatus, 
Holliston, MA, USA) for the duration of the experiment. Supplemental anaesthetic was administered 
as necessary to maintain a surgical plane of anaesthesia. Depth of anaesthesia was determined by 
assessment of pedal withdrawal reflex to noxious pinch. Peripheral capillary O2 saturation (SpO2) 
was monitored using a pulse oximeter clip (MouseOxTM, Starr Life Sciences Corporation, Oakmount, 
PA, USA). A thigh of each mouse was shaved and the pulse oximeter was attached. A tracheotomy 
was performed in the mid-cervical region. A bias flow of supplemental O2 (FiO2 = 0.60) was provided 
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to all animals during baseline conditions. End-tidal carbon dioxide (ETCO2) was measured using a 
MicroCapStar (CWE, Ardmore, PA, USA). A pressure-tip catheter (Mikro-Tip, Millar Inc., Houston, 
TX, USA) was inserted into the mouth and positioned in the thoracic oesophagus for the assessment 
of oesophageal pressure, an index of intrapleural sub-atmospheric pressure generated by the 
respiratory musculature during inspiration [13]. Oesophageal recordings displayed phasic sub-
atmospheric pressure swings during inspiration. For the measurement of diaphragm EMG, a 
concentric needle electrode (26G; Natus Manufacturing Ltd., Galway, Ireland) was inserted into the 
costal diaphragm for the continuous measurement of EMG activity. In a similar manner, a concentric 
needle electrode was inserted into the third intercostal space (T3) for the measurement of external 
intercostal EMG activity. EMG signals were amplified (×5000), band-pass filtered (50–5000 Hz) and 
integrated (50 ms time constant; Neurolog system, Digitimer Ltd., Welwyn Garden City, UK). All 
biological signals were passed through an analogue-to-digital converter (Powerlab r8/30; 
ADInstruments, Colorado Springs, CO, USA) and were acquired using LabChart 7 (ADInstruments) 
at a sampling frequency of 4 kHz. 
Experimental protocol: Following instrumentation, animals were allowed a period of 
stabilization for at least 10 min, prior to a 10 min baseline recording. Next, the trachea was occluded 
for 30–40 s until a plateau was observed in the inspiratory pressure recordings. Following this 
challenge, animals were allowed to recover and were then instrumented for the measurement of 
ETCO2 and tracheal airflow. Next, animals were vagotomized by bilateral section of the cervical vagi. 
Following vagotomy, respiratory parameters were recorded for 10 min under steady-state conditions 
following vagotomy. Next, animals were challenged with hypercapnic-hypoxia (15% O2 & 6% CO2; 3 
min) to examine the effects of chemostimulation on tracheal airflow. Following the experimental 
protocol, mice were euthanized by decapitation. Blood was collected in 1.5 mL Eppendorf tubes 
coated with 4% EDTA, which were centrifuged at 1,610 g for 10 min at 4 °C. Plasma samples were 
aliquoted and snap frozen in liquid nitrogen and stored at −80 °C. Tibia length and mass were 
examined as an index of somatic growth. The following organs were weighed (wet weight): spleen, 
kidney, lung, right heart ventricle and left heart ventricle and interscapular brown adipose tissue and 
epididymal white adipose tissue. 
Data analysis: Integrated inspiratory diaphragm and T3 external intercostal (EIC) EMG activity 
and peak inspiratory sub-atmospheric oesophageal pressure were analysed. The amplitudes of 
diaphragm and EIC EMG and oesophageal pressure were averaged under steady-state basal 
conditions and averaged for the 5 successive maximal sustained efforts (maximal response) of the 
airway occlusion challenge. VT was derived from tracheal airflow measurements following vagotomy 
during baseline and during hypercapnic-hypoxia. Data for oesophageal pressure and respiratory 
muscle EMGs in wild type and mdx mice were previously published in a separate report [13]. 
2.5. Ex Vivo Diaphragm Muscle Function 
The diaphragm muscle (rib and central tendon intact) was immediately excised and placed in a 
tissue bath at room temperature containing continuously gassed hyperoxic (95% O2/5% CO2) Krebs 
solution (in mM: NaCl, 120; KCl, 5; Ca2+ gluconate, 2.5; MgSO4, 1.2; NaH2PO4, 1.2; NaHCO3, 25; and 
glucose, 11.5) and d-tubocurarine (25 μM) prior to functional analysis. Diaphragm muscle 
preparations were suspended vertically between two platinum plate electrodes in a water-jacketed 
tissue bath at 35 °C containing Krebs solution and were continuously aerated with hyperoxia (95% 
O2 & 5% CO2). The rib was sutured to an immobile hook and remained in a fixed positon for the 
duration of the experiment. Using non-elastic string, the central tendon was attached to a lever 
connected to a dual-mode force transducer (Aurora Scientific Inc.; Aurora, ON, Canada). To 
determine muscle optimum length (Lo), the length of the muscle preparations were adjusted using a 
micro-positioner between intermittent twitch contractions [32,33]. The muscle length which revealed 
maximal isometric twitch force for a single isometric twitch stimulation (supramaximal stimulation, 
1 ms duration) was considered Lo. Diaphragm preparations were maintained at Lo for the duration 
of the protocol. 
Antioxidants 2019, 8, 581 5 of 26 
Experimental protocol: First, a single isometric twitch contraction was measured and peak 
isometric twitch force (Pt), contraction time (CT) and half-relaxation time (½  RT) were assessed. To 
examine the force-frequency relationship, muscle bundles were stimulated sequentially at 10, 20, 40, 
60, 80, 100, 120, 140 and 160 Hz (300 ms train duration). Contractions were interspersed by a 1 min 
interval. Following the isometric protocol, an isotonic contraction was elicited in preparations at 0% 
load to examine maximum unloaded muscle shortening and velocity of shortening [32,33]. 
Data analysis: Muscle bundle cross-sectional area (CSA) was determined for the purpose of 
normalizing muscle force to bundle size. CSA was calculated by dividing muscle mass (weight in 
grams) by the product of muscle Lo (cm) and muscle density (assumed to be 1.06 g.cm−3). Muscle force 
was divided by bundle CSA and expressed as specific force (N.cm−2). CT and ½  RT were measured 
as indices of isometric twitch kinetics and expressed in ms. For isotonic contractions, total muscle 
shortening was considered the total distance shortened during muscle contraction at 0% load. For 
total muscle shortening (Smax), data were expressed in absolute units (cm) and were further 
normalized to Lo and expressed in L.Lo−1. For the measurement of muscle shortening velocity (Vmax), 
the distance shortened during the initial 30 ms of an unloaded contraction was assessed [25,33,34] 
and determined in absolute units (cm.s−1) and was normalized to Lo and expressed in Lo.s−1. 
2.6. Muscle Immunofluorescence and Histology 
2.6.1. Tissue Preparation 
Sections of hemidiaphragm from wild type (n = 6), mdx (n = 7) and mdx + NAC-treated mice (n = 
4) were mounted on cubes of liver. Diaphragm samples were embedded in optimum cutting 
temperature embedding medium (OCT; VWR International, Dublin, Ireland) for cryoprotection and 
then frozen in isopentane (Sigma Aldrich, Wicklow, Ireland) cooled on dry ice. Samples were then 
stored at −80 °C for subsequent structural analysis. Serial transverse muscle sections (10 µm) were 
cut using a cyrostat (Leica CM3050; Leica Microsystems, Nussloch, Germany) at −22 °C and mounted 
across polylysine-coated glass slides (VWR International, Dublin, Ireland) allowing for a distribution 
of tissue on a given slide. 
2.6.2. Histological analysis 
To examine putative inflammatory cell infiltration of muscle fibres, tissue sections were stained 
with haematoxylin and eosin (H&E) using an autostainer (Leica ST5010 Autostainer XL, Leica 
Microsystems, Nussloch, Germany). For collagen staining, picro-sirius red (Leica Biosystems, 
Wetzlar, Germany) staining was completed. Slides were mounted using DPX mounting medium 
(Sigma-Aldrich, Wicklow, Ireland), air-dried and visualized on a bright field microscope (Olympus 
BX51) at ×10 magnification. 
Data analysis: A total of six tissue sections per animal were examined. Muscle histology was 
scored using ImageJ software. Putative inflammatory cell infiltration (the presence of cells in the 
extracellular matrix) was scored and expressed as a percentage of the total area of muscle. For slides 
stained with picro-sirius red, the microscope lighting exposure was standardized during imaging. 
Images were analysed using a colour balance threshold and the area of collagen was expressed as a 
percentage of the total area of muscle. Data generated from multiple images was averaged per animal 
before computing group means. 
2.6.3. Embryonic Myosin Heavy Chain and Laminin Immunofluorescence 
Embryonic myosin (MyHCEMB) immunofluorescence was carried out as a marker of fibre 
regeneration/remodelling [35]. Laminin immunofluorescence was used to examine the fibre size 
(minimum Feret’s diameter) distribution of the diaphragm muscle as well as to determine central 
nucleation of muscle fibres. Two slides were removed from the −80 °C freezer containing a minimum 
of four sections per slide, from two distinct regions of muscle tissue for each animal. A hydrophobic 
barrier was created around the individual tissue samples using a hydrophobic pen (ImmEdge TM 
Vector Labs, Peterborough, UK). Briefly, tissue samples were immersed in phosphate-buffered saline 
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(PBS) (0.01 M) containing 1% bovine serum albumin (BSA) for 15 min followed by 3 × 5 min PBS 
rinses. This was followed by a 30 min wash in PBS containing 5% goat serum (Sigma-Aldrich, 
Wicklow, Ireland). Before application of the primary embryonic mouse monoclonal antibody 
(developed by S. Schiaffino and obtained from the Developmental Studies Hybridoma Bank (DSHB) 
at the University of Iowa, IA, USA), slides were exposed to a mouse IgG blocker, M.O.M. blocking 
solution (Vector Lab Inc., Burlingame, CA, USA) for 1 h at room temperature. Following 3 × 5 min 
PBS washes, a cocktail of primary antibodies containing MyHCEMB (F1.652; 1:20) and rabbit anti-
laminin antibody (Sigma Aldrich, 1:500) diluted in 1% BSA in PBS was applied to the slides and 
incubated at 4 °C overnight in a humidity chamber. The next day, slides were washed for 3 × 5 min 
in PBS before the application of the corresponding secondary antibodies, AlexaFluor594-conjugated 
goat anti-mouse IgG1 (1:500, Jackson ImmunoResearch Ltd., Ely, UK) and fluorescein isothiocyanate 
(FITC)-conjugated goat anti-rabbit secondary antibody (1:250, Sigma Aldrich). Slides were incubated 
for 1 h in the dark at room temperature. Finally, slides were washed for 3 × 5 min rinses in PBS before 
the application of 4′,6-diamidino-2-phenylindole (DAPI; 1:4000, Sigma Aldrich) for 10 min to identify 
myonuclei, followed by a final 3 × 5 min rinse in PBS. Negative control experiments were run in 
parallel where the primary antibodies were omitted and the secondary antibodies were applied to 
ensure that immune-tagging was specific. 
Data analysis: For muscle fibre distribution, MyHCEMB expressing muscle fibres and central 
nucleation, muscle sections were viewed at ×10 magnification and images were captured using an 
Olympus BX51 microscope and an Olympus DP71 camera. Cell Sens™ (Olympus) was used to 
digitally capture the images. Images were taken at random areas across each muscle section with four 
muscle sections analysed per animal. Individual images of the laminin, DAPI and MyHCEMB fibres 
were captured and merged together using ImageJ software. A 600 μm × 600 μm grid with inclusion 
and exclusion borders was placed over the image for analysis [12]. From each muscle section, the 
number of fibres per area along with minimum Feret’s diameter of the individual muscle fibres was 
analysed using a specialized ImageJ macro [36]. Frequency histograms were constructed to illustrate 
the distribution of fibre size in muscle sections across groups in addition to the coefficient of variation 
of minimum Feret’s diameter. The number of centrally nucleated and MyHCEMB expressing muscle 
fibres were counted (using the ImageJ multi-point tool) and expressed relative to the total number of 
myofibres per recorded area. Data generated from multiple images were averaged per animal before 
computing group means. 
2.7. Assays 
2.7.1. Tissue Preparation 
Frozen diaphragm muscle samples were removed from storage at −80 °C, weighed and 
homogenized on ice in ice-cold modified radioimmunoprecipitation assay (1X RIPA) buffer, 
deionized H2O, 200 mM sodium fluoride (NaF), 100 mM phenylmethylsulfonylfluoride (PMSF), 1X 
protease cocktail inhibitor (Sigma Aldrich, Ireland) and 200 mM sodium orthovanadate (Naortho) at a 
5% w/v ratio using a general laboratory homogenizer (Omni-Inc., Kennesaw, GA, USA). 
Homogenates were allowed 20 min of lyse time on ice with intermittent vortexing. Homogenates 
were centrifuged in a U-320R centrifuge (Boeckel & Co., Hamburg, Germany) at 15,366 g at 4 °C for 
20 min to separate insoluble cellular fractions from protein homogenates. The protein-containing 
supernatant was removed and stored at −80 °C, and the pellet was discarded. The protein 
concentration of each sample was quantified using a bicinchoninic acid (BCA) assay (Pierce 
Biotechnology, Fisher Scientific, Dublin, Ireland) as per the manufacturer’s instructions, at a dilution 
of 1:10. 
2.7.2. Glutathione Reductase and Glutathione Peroxidase Activities, Total Glutathione (tGSH) 
Concentration and GSSG:GSH Ratio 
Glutathione reductase (GR) catalyzes the reduction of glutathione disulfide (GSSG) by 
nicotinamide adenine dinucleotide phosphate (NADPH) to produce reduced glutathione (GSH). GR 
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activity was measured in diaphragm muscle homogenates from all three groups: WT (n = 7), mdx (n 
= 7) and mdx + NAC (n = 7). Briefly, 50 μL (25 μg) of sample, 50 μL of KH2PO4 (0.4 M)/EDTA (4 mM; 
pH 7.5) buffer and 50 μL of oxidised GSSG (4 mM) was added in duplicate to wells of a clear 96-well 
plate. Controls were also plated in duplicate which included: (1) all assay components except 
oxidised GSSG and (2) all assay components except sample, to account for any non-specific reduction 
in samples tested. 50 μL of NADPH (0.4 mM) was quickly added to each well to initiate the reaction 
and the absorbance was measured at 340 nM every 15 s for 30 min at 37 °C. The oxidation of NADPH 
at this wavelength is reflected by a decrease in absorbance over time, proportional to GSSG reduction 
and thus GR activity. Data are expressed as mU mg−1 protein. Glutathione peroxidase (GPx) converts 
GSH to GSSG while also reducing lipid hyperoxides to alcohols, and hydrogen peroxide (H2O2) to 
water. GPx activity was measured in diaphragm muscle homogenates from WT (n = 7), mdx (n = 7) 
and mdx + NAC (n = 7) groups using a commercially available kit (catalogue number. ABE3639; 
Source BioScience, Nottingham, UK) as per the manufacturer’s instructions. Data are expressed as 
nmol min−1 mg−1 protein. Total glutathione (tGSH) comprises GSH + GSSG, which can be used to 
calculate the GSSG:GSH ratio, a common measure of oxidative stress. tGSH and GSSG concentration 
were measured in diaphragm muscle homogenates from wild type (n = 7), mdx (n = 7) and mdx + NAC 
(n = 7) groups using a commercially available kit (catalogue number. 703002; Cayman Chemical, Ann 
Arbor, MI, USA) as per the manufacturer’s instructions, with data expressed as μM mg−1 protein and 
GSSG:GSH. 
2.7.3. Cytokine Multiplex Assay 
A multiplex cytokine assay (K15048G-1; Meso Scale Discovery, Rockville, MD, USA) was used 
to examine cytokine concentrations in diaphragm muscle (200 µg well−1; n = 7 per group) and plasma 
samples (1:2 dilution; n = 8–10 per group) from all 3 groups. The assay was performed according to 
the manufacturer’s instructions using an extended incubation time to improve the detection of 
cytokines in diaphragm muscle homogenates (the plate was incubated overnight at 4 °C) [17]. 
Following incubation, the plate was read on a Quickplex SQ 120 imager (Meso Scale Discovery). 
2.8. Gene Expression 
2.8.1. RNA Extraction and Preparation 
Diaphragm muscle samples were removed from storage at −80 °C, weighed and samples ranging 
from 20–50 mg were homogenized on ice in Tripure Isolation Reagent (Roche Diagnostics, Ltd., 
Burgess Hill, UK) using a general laboratory homogenizer (Omni-Inc., Kennesaw, GA, USA). Total 
RNA was isolated from homogenates in accordance with the manufacturer’s instructions, with an 
additional chloroform wash step performed during phase separation. The quantity (ng μL−1) and 
purity of isolated RNA (260:280 & 260:230 ratios) was assessed using a Nanodrop 1000 (Thermo 
Scientific, Waltham, MA, USA) and spectrophotometry. The integrity of isolated RNA was assessed 
by visualization of distinct 18S and 28S ribosomal RNA bands using an agarose gel electrophoresis 
system (E-gel, Life Technologies, Carlsbad, CA, USA). 
2.8.2. Reverse Transcription 
Diaphragm muscle RNA was reverse transcribed to cDNA using a Transcriptor First Strand 
cDNA Synthesis Kit (Roche Diagnostics Ltd., Burgess Hill, UK) in accordance with the 
manufacturer’s instructions. 
2.8.3. qRT-PCR 
cDNA was amplified using Realtime ready Catalog or Custom assays (Roche Diagnostics Ltd., 
Burgess Hill, UK) shown in Table 1 and Fast Start Essential Probe Master (Roche Diagnostics Ltd., 
Burgess Hill, UK) as per the manufacturer’s instructions. Briefly, all reactions were carried out in 
duplicate on a 96-well plate and consisted of 5 µL cDNA and 15 µL master mix using the Lightcycler 
Antioxidants 2019, 8, 581 8 of 26 
96 (Roche Diagnostics Ltd., Burgess Hill, UK). RNA negatives, reverse transcription negatives, cDNA 
negatives (no template controls) and plate calibrators were used on every plate. Quantification cycle 
values (Cq) obtained from experiments for the genes of interest (Nfkb1, Fbxo32, Trim63, Map1lc3b, 
Gabarapl1, Bnip3, Cybb, Park2, Pink, Nfe2l2, Cat, Mstn, Myod1, Gpx2, Myog, Sod2, Sod1, Sirt1, Igf1 and 
Mef2c) were normalized to that of a reference gene, Hprt1, to account for variations in input amounts 
of RNA/cDNA and the efficiency of reverse transcription. Hprt1 was found to be the most stable gene 
of the candidate reference genes screened, in consideration of genotype and drug treatment (NAC). 
The relative gene expression was calculated using the ∆∆CT method (normalized expression of the 
gene of interest to that of the reference gene), with a change in expression shown as a fold change 
relative to the control group (wild type). 
Table 1. Real-time ready catalog and custom assays used for cDNA amplification. 
Gene Title Gene Symbol Assay ID 
Atrogin1 Fbxo32 317844 
BNIP3 Bnip3 311465 
Catalase Cat 310718 
GABARAPL1 Gabarapl1 317923 
GPX2 Gpx2 318630 
HPRT Hprt 307879 
IGF1 Igf1 313359 
LC3B Map1lc3b 317920 
MEF2C Mef2c 318629 
Myogenin Myog 313501 
Myostatin Mstn 318626 
MyoD Myod1 313570 
MuRF1 Trim63 317843 
NFκB Nfkb1 300085 
NOX2 Cybb 317885 
Nrf2 Nfe2l2 313377 
PARK2 Park2 317264 
PINK1 Pink1 331846 
Sirtuin1 Sirt1 310480 
SOD1 Sod1 310738 
SOD2 Sod2 310295 
2.9. Statistical Analysis 
Data are expressed as mean ± SD or as box and whisker plots (median, 25–75th percentile and 
scatter plot). Using Prism, version 6.0 (Graphpad Software Inc., San Diego, CA, USA), data from each 
group were statistically analysed and assessed for normal distribution and equal variances. Data sets 
that were of equal variance and normally distributed were compared statistically using one-way 
analysis of variance (ANOVA) with a Newman–Keuls post hoc test. Kruskal-Wallis with Dunn’s post 
hoc test was applied to group data that were not of Gaussian distribution. Diaphragm muscle force-
frequency relationship was statistically analysed using repeated measures two-way ANOVA with a 
Bonferroni post hoc test. P values are reported. 
3. Results 
3.1. Body Mass and Organ Measurements 
Table 2 compares body mass, tibia length and mass, organ mass and brown and white adipose 
mass in wild type, mdx and mdx mice treated with 1% NAC (mdx + NAC). Body mass for mdx mice 
was unaffected by NAC supplementation (P > 0.05; Kruskal-Wallis with Dunn’s post hoc test). Right 
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and left ventricle mass was increased for mdx mice (P < 0.0001 and P < 0.01; one-way ANOVA with 
Newman-Keuls post hoc test and Kruskal–Wallis with Dunn’s post hoc test; right and left ventricle, 
respectively). The ratio of right to left ventricle mass (RV:LV) was increased in mdx (P < 0.05; one-way 
ANOVA with Newman–Keuls post hoc test); RV:LV was unaffected by NAC. Spleen mass was 
increased in mdx (P < 0.0001) compared with wild type and was further increased in mdx mice 
following NAC intervention (P < 0.01). Brown and white adipose tissue mass were lower in mdx (P < 
0.01 and P < 0.001; one-way ANOVA with Newman–Keuls post hoc test and Kruskal-Wallis with 
Dunn’s post hoc test; brown and white, respectively) compared with wild type. Brown and white 
adipose tissue mass was unchanged by NAC administration. Tibia length and mass, and kidney and 
lung mass were equivalent in all three groups (Table 2). 
Table 2. Body mass, tibia mass and length, organ mass and adipose tissue mass. Definition of 
abbreviations: NAC, N-acetylcysteine; RV, right heart ventricle; LV, left heart ventricle; BAT, brown 
adipose tissue; eWAT, epididymal white adipose tissue. Mdx + NAC group received 1% N-
acetylcysteine in the drinking water for 14 days. Data are shown as mean ± SD and were statistically 
compared using one-way ANOVA with Newman-Keuls post hoc test, or Kruskal-Wallis with Dunn’s 
post hoc test. * denotes mdx different from corresponding wild type group; * P < 0.05, ** P < 0.01, *** P 
< 0.001 and **** P < 0.0001. $ denotes mdx + NAC different from corresponding mdx group; $ P < 0.05 
and $$ P < 0.01. 
 
Wild type 
(n = 10) 
mdx 
(n = 10) 
mdx + NAC 
(n = 10) 
P Value 
Body mass (g) 24.8 ± 1.5 26.0 ± 0.8 26.7 ± 1.6 P = 0.0194 
Tibia length (mm) 16.3 ± 0.7 16.4 ± 1.1 16.2 ± 0.7 P = 0.9528 
Tibia mass (mg) 40.7 ± 4.1 39.9 ± 6.4 38.8 ± 4.5 P = 0.7019 
RV (mg) 20.6 ± 3.6 28.9 ± 2.8 **** 25.6 ± 2.2 $ P < 0.0001 
LV (mg) 70.2 ± 5.1 82.7 ± 7.9 ** 79.5 ± 7.8 P = 0.0048 
RV:LV 0.29 ± 0.06 0.35 ± 0.05 * 0.33 ± 0.05 P = 0.0411 
Spleen (mg) 58.4 ± 7.2 99.0 ± 10.1 **** 119.9 ± 25.0 $$ P < 0.0001 
Kidney (mg) 301.7 ± 26.4 322.9 ± 64.2 359.8 ± 31.0 P = 0.004 
Lung (mg) 136.4 ± 14.4 150.9 ± 36.2 159.3 ± 36.2 P = 0.4124 
BAT (mg) 64.2 ± 9.0 43.8 ± 14.2 ** 53.5 ± 7.5 P = 0.0048 
eWAT (mg) 407.8 ± 43.2 216.2 ± 57.3 *** 217.9 ± 58.3 P < 0.0001 
3.2. Baseline Ventilation and Ventilatory Responsiveness to Hypercapnic-Hypoxia in Conscious Mice 
Respiratory parameters including fR, VT and VE during baseline (21% O2) and hypercapnic-
hypoxia (10% O2 & 6% CO2) are shown in Table 3. During baseline conditions, fR, VT and VE were 
equivalent between all three groups. During exposure to hypercapnic-hypoxia, VT was lower in mdx 
(P < 0.05; Kruskal–Wallis with Dunn’s post hoc test) compared with wild type, fR and VE were 
equivalent between wild type and mdx. NAC did not alter fR, VT and VE during hypercapnic-hypoxia. 
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Table 3. Baseline ventilation in conscious mice. Definition of abbreviations: fR, respiratory frequency; 
NAC, N-acetylcysteine; VE, minute ventilation; VT, tidal volume. Mdx + NAC group received 1% N-
acetylcysteine in the drinking water for 14 days. Data are shown as mean ± SD and were statistically 
compared using one-way ANOVA with Newman-Keuls post hoc test, or Kruskal-Wallis with Dunn’s 
post hoc test. * denotes mdx different from corresponding wild type group; * P < 0.05. 
 
Wild type 
(n = 10) 
mdx 
(n = 8) 
mdx + NAC 
(n = 10) 
P Value 
Normoxia (21% O2) 
fR (brpm) 196 ± 15 211 ± 14 205 ± 16 P = 0.1136 
VT (mL g−1 body mass) 0.007 ± 0.001 0.006 ± 0.001 0.006 ± 0.001 P = 0.1295 
VE (mL g−1 min−1) 1.31 ± 0.15 1.28 ± 0.25 1.29 ± 0.10 P = 0.8891 
Hypercapnic-Hypoxia (10% O2 & 6% CO2) 
fR (brpm) 366 ± 28 360 ± 61 369 ± 15 P = 0.8817 
VT (mL g−1 body mass) 0.014 ± 0.002 0.011 ± 0.002 * 0.012 ± 0.001 P = 0.0147 
VE (mL g−1 min−1) 5.01 ± 0.98 3.99 ± 1.24 4.56 ± 0.47 P = 0.0903 
Body mass (g) 24.8 ± 1.5 26.1 ± 0.8 26.7 ± 1.6 P = 0.0222 
3.3. Inspiratory Pressure and Diaphragm and Intercostal EMGs during Airway Obstruction in 
Anaesthetized Mice 
Previously, we reported findings from recordings of oesophageal pressure and diaphragm and 
external intercostal EMG activities for two of the groups, wild type and mdx, in the context of a 
comprehensive assessment of respiratory system deficits and compensations in young mdx mice [13]. 
Here, we compare values for the mdx + NAC group to our previously published values. During 
baseline recordings, oesophageal pressure (P = 0.9843; Kruskal–Wallis test; Table 4) and diaphragm 
(P = 0.0907; Kruskal-Wallis test; Table 4) and external intercostal (P > 0.05; one-way ANOVA with 
Newman-Keuls post hoc test; Table 4) EMG activities in mdx + NAC were equivalent to values for mdx. 
In anaesthetized mice, protracted airway obstruction increased oesophageal sub-atmospheric 
pressure generation and EMG activity in all groups, measured as the average of five consecutive peak 
inspiratory efforts. Compared with mdx mice, oesophageal pressure (P = 0.0954; one-way ANOVA; 
Table 4) and diaphragm (P = 0.1741; Table 4) and external intercostal (P > 0.05; Kruskal–Wallis with 
Dunn’s post hoc test; Table 4) EMG activities were not different following NAC administration during 
protracted airway occlusion. 
Table 4. Oesophageal pressure and diaphragm and T3 external intercostal (EIC) EMG activities 
during baseline and tracheal occlusion in anaesthetized mice. Definition of abbreviations: NAC, N-
acetylcysteine; dia, diaphragm; EIC, external intercostal; NAC, N-acetylcysteine; A.U., arbitrary units. 
Mdx + NAC group received 1% N-acetylcysteine in the drinking water for 14 days. Sustained tracheal 
occlusion was reported as the average of five successive peak breaths. Data are shown as mean ± SD 
and were statistically compared using one-way ANOVA with Newman–Keuls post hoc test, or 
Kruskal-Wallis with Dunn’s post hoc test. * denotes mdx different from corresponding wild type group; 
** P < 0.01. 
 
Wild type 
(n = 10) 
mdx 
(n = 10) 
mdx + NAC 
(n = 10) 
P Value 
 Baseline 
Inspiratory pressure (cmH2O) −9.0 ± 3.0 −9.2 ± 3.5 −9.3 ± 3.4 P = 0.9843 
Dia EMG Amplitude (A.U.) 9.6 ± 6.7 5.5 ± 5.3  5.5 ± 3.7 P = 0.0907 
T3 EIC EMG Amplitude (A.U.) 6.2 ± 2.7 3.3 ± 2.0 ** 3.2 ± 1.1 P = 0.0027 
 Obstruction 
Inspiratory pressure (cmH2O) −67.5 ± 10.2 −59.7 ± 11.8 −55.4 ± 13.3 P = 0.0954 
Dia EMG Amplitude (A.U.) 38.6 ± 16.2 25.0 ± 14.6 30.4 ± 16.8 P = 0.1741 
T3 EIC EMG Amplitude (A.U.) 43.7 ± 19.9 14.3 ± 9.3 ** 18.1 ± 12.5 P = 0.0011 
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3.4. Tracheal Airflow in Anaesthetized Mice 
Table 5 shows respiratory data in anaesthetized wild type, mdx and mdx + NAC mice during 
baseline conditions (60% O2) and hypercapnic-hypoxia (FiO2 = 0.15 & FiCO2 = 0.05) in vagotomized 
mice. All respiratory parameters were equivalent comparing wild type, mdx and mdx + NAC mice. 
Table 5. Respiratory measurements in anaesthetized mice in vivo. Definition of abbreviations: ETCO2, 
end-tidal carbon dioxide; fR, respiratory frequency; NAC, N-acetylcysteine; PIF, peak inspiratory 
flow; PEF, peak expiratory flow; SpO2, peripheral capillary oxygen saturation; VE, minute ventilation; 
VT, tidal volume. Mdx + NAC group received 1% N-acetylcysteine in the drinking water for 14 days. 




(n = 10) 
mdx 
(n = 7–8) 
mdx + NAC 
(n = 8–10) 
P Value 
Baseline Post-Vagotomy (60% O2) 
fR (brpm) 65 ± 21 61 ± 12 69 ± 19 P = 0.7421 
VT (mL g−1) 0.028 ± 0.005 0.029 ± 0.003 0.030 ± 0.008 P = 0.8468 
VE (mL g−1 min−1) 1.8 ± 0.4 1.8 ± 0.3 1.9 ± 0.2 P = 0.5651 
PIF (mL g−1 sec−1) 1.10 ± 0.22 1.14 ± 0.12 1.12 ± 0.41 P = 0.9498 
PEF (mL g−1 sec−1) 1.08 ± 0.17 1.17 ± 0.27 1.20 ± 0.26 P = 0.5177 
ETCO2 (mmHg) 53.3 ± 3.4 49.6 ± 7.9 52.9 ± 3.3 P = 0.3033 
SpO2 (%) 94.9 ± 2.3 95.1 ± 2.4 93.5 ± 4.1 P = 0.5320 
Hypercapnic-Hypoxia (15% O2 & 6% CO2) 
fR (brpm) 57 ± 17 52 ± 12 62 ± 16 P = 0.4772 
VT (mL g−1) 0.041 ± 0.007 0.046 ± 0.005 0.043 ± 0.009 P = 0.604 
VE (mL g−1 min−1) 2.3 ± 0.7 2.4 ± 0.6 2.6 ± 0.4 P = 0.6929 
PIF (mL g−1 sec−1) 1.43 ± 0.23 1.45 ± 0.14 1.43 ± 0.35 P = 0.611 
PEF (mL g−1 sec−1) 1.15 ± 0.19 1.38 ± 0.18 1.29 ± 0.20 P = 0.0655 
SpO2 (%) 59.8 ± 5.9 64.6 ± 9.8 55.7 ± 6.3 P = 0.0865 
3.5. Diaphragm Muscle Contractile Function Ex Vivo 
Table 6 shows data for twitch contractile kinetics (CT and ½  RT) and isotonic contractile kinetics 
(Smax and Vmax) of diaphragm muscle preparations from all three groups. Diaphragm CT and ½  RT 
were equivalent in wild type and mdx preparations; NAC had no effect on CT and ½  RT for mdx 
diaphragm. Absolute values for Smax were reduced in mdx (P < 0.01; Kruskal-Wallis with Dunn’s post 
hoc test) diaphragm preparations compared with wild type. NAC supplementation in mdx mice 
increased diaphragm Smax and Vmax (P < 0.05 and P < 0.05, Smax and Vmax respectively; Kruskal-Wallis 
with Dunn’s post hoc test). Normalized values for Smax and Vmax were equivalent in all three groups. 
Table 6. Ex vivo respiratory muscle contractile kinetics. Definition of abbreviations: ½  RT, half-
relaxation time; CSA, cross-sectional area; CT, contraction time; Lo, optimum length; NAC, N-
acetylcysteine; Pt, twitch force; Po, tetanic force; Smax, maximum unloaded shortening; Vmax, maximum 
shortening velocity. Mdx + NAC group received 1% N-acetylcysteine in the drinking water for 14 
days. Data are shown as mean ± SD and were statistically compared using one-way ANOVA with 
Newman-Keuls post hoc test, or Kruskal-Wallis with Dunn’s post hoc test. * denotes mdx different from 
corresponding WT group; ** P < 0.01 and *** P < 0.001. $ denotes mdx + NAC different from 
corresponding mdx group; $ P < 0.05 and $$ P < 0.01. 
 
Wild type 
(n = 10) 
mdx 
(n = 8-9) 
mdx + NAC 
(n = 10) 
P Value 
CT (ms) 17.2 ± 2.6 18.1 ± 4.0 19.2 ± 2.5 P = 0.3816 
½  RT (ms) 19.9 ± 6.9 21.7 ± 9.0 22.5 ± 4.2 P = 0.7034 
Smax (cm) 0.39 ± 0.08 0.23 ± 0.06 ** 0.36 ± 0.05 $ P = 0.0014 
Smax (L Lo−1) 0.37 ± 0.06 0.31 ± 0.08 0.35 ± 0.03 P = 0.1016 
Vmax (cm s−1) 4.1 ± 1.0 2.3 ± 1.2 4.4 ± 1.0 $ P = 0.0184 
Vmax (Lo s−1) 4.0 ± 1.0 3.2 ± 1.7 4.2 ± 0.7 P = 0.3223 
Lo (cm) 1.1 ± 0.1 0.8 ± 0.1 *** 1.0 ± 0.1 $$ P = 0.0004 
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Figure 1 shows representative original traces for diaphragm muscle twitch (A) and tetanic (B) 
contractions, force-frequency relationship (C) and maximum unloaded shortening (D). NAC 
treatment increased diaphragm twitch force in mdx (Figure 1E, Pt; P < 0.01; Kruskal–Wallis with 
Dunn’s post hoc test) compared with mdx. Diaphragm tetanic force at 100 Hz was lower in mdx (Figure 
1E, Po; P < 0.001; Kruskal–Wallis with Dunn’s post hoc test) compared with wild type. NAC treatment 
increased mdx diaphragm tetanic force (Figure 1E, Po; P < 0.05; Kruskal–Wallis with Dunn’s post hoc 
test) compared with mdx. For the force-frequency relationship, diaphragm specific force was reduced 
in mdx compared with wild type preparations (Figure 1F; P < 0.0001; repeated measures two-way 
ANOVA). Post hoc analysis revealed differences between wild type and mdx diaphragm across a 
broad stimulus range (40–160 Hz). NAC supplementation to mdx mice improved diaphragm force-
generating capacity compared with mdx preparations (Figure 1F; P < 0.0001; repeated measures two-
way ANOVA). Post hoc analysis indicated an improvement in mdx diaphragm force-generating 
capacity following NAC supplementation across a broad stimulus range (60–160 Hz). 
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Figure 1. Ex vivo diaphragm muscle contractile force. A–D, original traces of ex vivo diaphragm 
muscle twitch force (A), tetanic force at 100Hz (B), maximum unloaded shortening (C) and force-
frequency relationship (D) for wild type (WT), mdx and mdx + N-acetylcysteine (NAC) preparations. 
E and F, group data for ex vivo diaphragm muscle twitch (E; Pt) and tetanic (E; Po) force and force-
frequency relationship (F) in wild type, mdx and mdx + NAC preparations. Mdx + NAC group received 
1% N-acetylcysteine in the drinking water for 14 days. For Pt and Po, values are expressed as scatter 
point box and whisker plots (median, 25–75 percentile and scatter plot) and were statistically 
compared by Kruskal-Wallis with Dunn’s post hoc test. For force-frequency, data are shown as mean 
± SD and were statistically compared using repeated measures two-way ANOVA with Bonferroni 
post hoc test. * denotes mdx different from corresponding WT group; ** P < 0.01, *** P < 0.001. $ denotes 
mdx + NAC different from corresponding mdx group; $ P < 0.05, $$ P < 0.01, $$$ P < 0.001. 
3.6. Diaphragm Muscle Histology and Immunofluorescence 
Figure 2A–E shows representative images for diaphragm muscle histology and 
immunohistochemistry for all three groups. The areal density of inflammatory cell infiltration was 
increased in mdx diaphragm compared with wild type (Figure 2F; P < 0.001; one-way ANOVA with 
Newman–Keuls post hoc test). There was a reduction in immune cell infiltration in mdx diaphragm 
following NAC treatment compared with mdx diaphragm (Figure 2F; P < 0.05). The areal density of 
collagen labelled with Sirius red staining was increased in mdx diaphragm compared with wild type 
(Figure 2G; P < 0.001). NAC treatment in mdx resulted in a reduction in collagen deposition compared 
with untreated mdx mice (Figure 2G; P < 0.01). There was a reduction in muscle fibre size (minimum 
Feret’s diameter) for mdx diaphragm compared with wild type (Figure 2H; P < 0.01); NAC treatment 
had no effect on fibre size. The proportion of diaphragm muscle fibres with centrally located 
myonuclei was increased in mdx compared with wild type (Figure 2I; P < 0.01; Kruskal–Wallis with 
Dunn’s post hoc test); NAC had no effect on the proportion of centrally located myonuclei. The 
proportion of diaphragm muscle fibres expressing embryonic myosin was increased in mdx 
diaphragm compared with wild type (Figure 2J; P < 0.01; one-way ANOVA with Newman–Keuls post 
hoc test); NAC treatment had no effect on central nucleation and embryonic myosin expression in 
mdx diaphragm. The coefficient of variation of muscle fibre size was increased in mdx diaphragm 
compared with wild type (Figure 2K; P < 0.0001); NAC treatment had no effect on fibre size 
variability. There was a wider distribution of muscle fibre size (based on minimum Feret’s diameter) 
in mdx diaphragm compared with wild type (Figure 2L). The distribution of diaphragm muscle fibres 
in mdx + NAC was similar to mdx mice, with a slightly greater abundance of large fibres. 
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Figure 2. Diaphragm muscle histology and immunofluorescence. A and B, representative histological 
images of transverse sections of diaphragm muscle stained with Haematoxylin and Eosin (A) and 
Sirius red (B) in wild type (WT), mdx and mdx + NAC groups. Mdx + NAC group received 1% N-
acetylcysteine in the drinking water for 14 days. C-E, representative images of diaphragm muscle 
immunofluorescently labelled for laminin (C), laminin, DAPI and embryonic myosin (D) and 
embryonic myosin and DAPI (E) for WT, mdx and mdx + NAC groups. Scale bars represent 100 μm in 
A, B, C and E. In D, scale bars represent 50 μm. F–J, group data showing the relative area of infiltration 
of inflammatory cells (F), relative area of collagen deposition (G), muscle fibre size measured by 
minimum Feret’s diameter (H), relative area of centrally nucleated diaphragm muscle fibres (I) and 
relative area of diaphragm muscle fibres expressing embryonic myosin (J) in diaphragm muscle from 
WT, mdx and mdx + NAC groups. K-L, group data for the coefficient of variation of muscle fibre size 
(K) and the frequency distribution of muscle fibre size (L) for all three groups. Values are expressed 
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as scatter point box and whisker plots (median, 25–75 percentile and scatter plot) and were statistically 
compared using one-way ANOVA with Newman-Keuls post hoc test, or Kruskal-Wallis with Dunn’s 
post hoc test. * denotes mdx different from corresponding WT group; ** P < 0.01, *** P < 0.001 and **** 
P < 0.0001. $ denotes mdx + NAC different from corresponding mdx group; $ P < 0.05 and $$ P < 0.01. 
3.7. Diaphragm Glutathione Status 
Glutathione reductase activity was increased in mdx diaphragm (Figure 3A; P < 0.01; one-way 
ANOVA with Newman-Keuls post hoc test) compared with wild type. GSSG:GSH was decreased in 
mdx diaphragm (Figure 3D; P < 0.05; Kruskal-Wallis with Dunn’s post hoc test) compared with wild 
type. Diaphragm glutathione peroxidase and total glutathione were equivalent in all three groups. 
Diaphragm glutathione reductase, glutathione peroxidase, total glutathione and GSSG:GSH were all 
unaffected by NAC supplementation in mdx mice. 
 
Figure 3. Diaphragm muscle glutathione status. A and B, group data for glutathione reductase (A) 
and glutathione peroxidase (B) activities of diaphragm muscle from wild type (WT), mdx and mdx + 
NAC groups. Mdx + NAC group received 1% N-acetylcysteine in the drinking water for 14 days. C 
and D, group data for total glutathione (C) and the ratio of oxidised glutathione (GSSG) to glutathione 
(GSSG:GSH; D). Values are expressed as scatter point box and whisker plots (median, 25–75 percentile 
and scatter plot) and were statistically compared using one-way ANOVA with Newman-Keuls post 
hoc test, or Kruskal–Wallis with Dunn’s post hoc test. * denotes mdx different from corresponding WT 
group; * P < 0.05 and ** P < 0.01. 
3.8. Plasma and Diaphragm Cytokine Concentrations 
Plasma samples from mdx mice had increased concentration of the cytokines, IL-1β (Figure 4A; 
P < 0.01; one-way ANOVA with Newman–Keuls post hoc test), IL-5 (Figure 4A; P < 0.05); IL-6 (Figure 
4B; P < 0.01; Kruskal–Wallis with Dunn’s post hoc test) and IL-10 (Figure 4A; P < 0.05; Kruskal–Wallis 
with Dunn’s post hoc test). The chemokine KC/GRO was increased in mdx plasma (Figure 4B; P < 0.01; 
one-way ANOVA with Newman–Keuls post hoc test) compared with wild type. NAC 
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supplementation decreased the concentration of IL-1β (Figure 4A; P < 0.01; one-way ANOVA with 
Newman–Keuls post hoc test) and KC/GRO (Figure 4B; P < 0.05; one-way ANOVA with Newman–
Keuls post hoc test) in mdx plasma. Plasma IFN-γ (Figure 4A), IL-2 (Figure 4A), IL-4 (Figure 4A) and 
TNF-α (Figure 4A) concentrations were equivalent in all three groups. Increased levels of IL-1β 
(Figure 4C; P < 0.001; Kruskal-Wallis with Dunn’s post hoc test), IL-6 (Figure 4D; P < 0.05; Kruskal–
Wallis with Dunn’s post hoc test) and KC/GRO (Figure 4D; P < 0.01; one-way ANOVA with Newman–
Keuls post hoc test) were observed in mdx diaphragm. Post hoc analysis revealed no changes in mdx 
diaphragm IL-1β, IL-6 or KC/GRO concentrations following NAC (P >0.05) but notably the 
concentrations of IL-1β and IL-6 in diaphragms from mdx + NAC were >50% reduced compared with 
mdx. Diaphragm IFN-γ (Figure 4C), IL-2 (Figure 4C), IL-4 (Figure 4C), IL-5 (Figure 4C), IL-10 (Figure 
4C), TNF-α (Figure 4C) and IL-12p70 (Figure 4D) were equivalent in all three groups. 
 
Figure 4. Plasma and diaphragm muscle cytokine concentrations. A–D, group data for selective 
cytokine concentrations in plasma and diaphragm muscle from wild type (n = 7), mdx (n = 7–9) and 
mdx + NAC (n = 7–9) groups. Mdx + NAC group received 1% N-acetylcysteine in the drinking water 
for 14 days. Plasma cytokines include interferon-γ (IFN-γ; A), interleukin-1β (IL-1β; A), interleukin-2 
(IL-2; A), interleukin-4 (IL-4; A), interleukin-5 (IL-5; A), interleukin-6 (IL-6; B), interleukin-10 (IL-10; 
A), KC/GRO (B), tumour necrosis factor-α (TNF-α; A). Diaphragm cytokines include IFN-γ (C), IL-
1β (C), IL-2 (C), IL-4 (C), IL-5 (C), IL-6 (D), IL-10 (P), KC/GRO (D), IL-12 (IL-12p70; D) and TNF-α (C). 
Data are shown as mean ± SD and were statistically compared using one-way ANOVA with 
Newman–Keuls post hoc test, or Kruskal–Wallis with Dunn’s post hoc test. * denotes mdx different from 
corresponding WT group; * P < 0.05, ** P < 0.01 and ***P < 0.001. $ denotes mdx + NAC different from 
corresponding mdx group; $ P < 0.05.  
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3.9. Diaphragm Muscle mRNA Expression 
Figure 5 shows data for mRNA expression of genes related to redox status, inflammation, muscle 
repair, autophagy and mitophagy in diaphragm muscle from wild type, mdx and mdx + NAC groups. 
There was increased expression of the pro-inflammatory transcription factor NFκB in mdx diaphragm 
(Figure 5A; P = 0.0184; one-way ANOVA with Newman-Keuls post hoc test) compared with wild type; 
NAC administration had no effect. The expression of the reactive oxygen species generating complex 
NOX2 was increased in mdx diaphragm (Figure 5A; P < 0.0001) and was unaffected by NAC 
administration. Expression of the antioxidant response element, Nrf2, was similar in wild type and 
mdx diaphragm (P > 0.05); Nrf2 expression was increased in mdx + NAC compared with mdx (Figure 
5A; P < 0.01). Expression of the antioxidant gene SOD1 was decreased in mdx diaphragm (Figure 5A; 
P < 0.01) compared with wild type; NAC treatment in mdx had no effect. There were no differences 
between groups for SOD2 and GPX2 in post hoc analyses. 
The muscle repair genes MyoD and Myogenin had increased mRNA expression in mdx 
diaphragm (Figure 5B; P < 0.001 and P = 0.01; MyoD and Myogenin respectively; one-way ANOVA 
with Newman-Keuls post hoc test and Kruskal–Wallis with Dunn’s post hoc test respectively); NAC 
treatment in mdx had no effect on both genes. mRNA expression of Myostatin, an inhibitor of 
myogensis, was reduced in mdx diaphragm (Figure 5B; P < 0.01; one-way ANOVA with Newman–
Keuls post hoc test) compared with wild type diaphragm; NAC treatment in mdx had no effect. The 
muscle differentiation transcription factor MEF2C had reduced mRNA expression in mdx diaphragm 
compared with wild type (Figure 5B; P < 0.05) and was unaffected by NAC treatment in mdx. 
The atrophy-related gene MuRF1 had increased mRNA expression in mdx diaphragm (Figure 
5B; P < 0.01) compared with wild type; MuRF1 expression was unaffected by NAC administration. 
The mitophagy-related gene PARK2, had increased mRNA expression in mdx diaphragm (Figure 5C; 
P < 0.05) compared with wild type; PARK2 mRNA expression was unaffected by NAC treatment in 
mdx. There were no differences between groups for GABARAPL1 in post hoc analyses. mRNA 
expression of Catalase (Figure 5A), Sirtuin1 (Figure 5A), IGF1 (Figure 5B), Atrogin1 (Figure 5B), 
PINK1 (Figure 5C), LC3B (Figure 5C) and BNIP3 (Figure 5C) was equivalent in all three groups. 
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Figure 5. Diaphragm muscle mRNA expression. Definition of abbreviations: BNIP-3, BCL3 interacting 
protein; GPX, glutathione peroxidase; GABARAPL1, GABA type A receptor associated protein Like 
1; IGF, insulin-like growth factor; LC3B, light chain 3 beta; MEF2C, myocyte enhancer factor 2C; 
MyoD, myogenic differentiation; Murf-1, muscle RING-finger protein-1; NAC, N-acetylcysteine; 
NOX, NADPH oxidase; NRf-2, nuclear factor (erythroid-derived 2)-like 2; NFκB, nuclear factor 
kappa-light-chain-enhancer of activated B cells; PARK-2, parkin RBR E3 ubiquitin protein ligase; 
PINK-1, phosphatase and tensin homolog (PTEN)-induced kinase 1; SOD, superoxide dismutase; WT, 
wild type. A–C, group data for mRNA expression of NFκB (A), NOX2 (A), Nrf2 (A), SOD1 (A), SOD2 
(A), GPX2 (A), catalase (A), sirtuin1 (A), MyoD (B), IGF1 (B), MEF2C (B), myogenin (B), myostatin 
(B), atrogin1 (B), MuRF1 (B), LC3B (C), GABARAPL1 (C), BNIP3 (C), PINK1 (C) and PARK2 (C) in 
diaphragm muscle from wild type (WT; n = 7–8), mdx (n = 6–7) and mdx + NAC (n = 6–7) groups. Mdx 
+ NAC group received 1% N-acetylcysteine in the drinking water for 14 days. Data are shown as mean 
± SD and were statistically compared using one-way ANOVA with Newman-Keuls post hoc test, or 
Kruskal-Wallis with Dunn’s post hoc test. * denotes mdx different from corresponding WT group; * P 
< 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001. $ denotes mdx + NAC different from corresponding 
mdx group; $$ P < 0.01. 
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4. Discussion 
The major findings of the study are: (i) NAC supplementation improved mdx diaphragm 
functional capacity (ii) NAC supplementation reduced collagen deposition (fibrosis) and immune cell 
infiltration in mdx diaphragm; (iii) NAC treatment reduced IL-1β and KC/GRO concentrations in mdx 
plasma samples; (iv) NAC increased Nrf2 mRNA expression in mdx diaphragm; (v) NAC had no 
adverse effect on ventilation, inspiratory pressure and respiratory muscle EMG or growth measures 
in mdx mice; (vi) NAC did not recover decreased respiratory muscle EMG activity in mdx mice during 
maximum activation (airway obstruction). 
Dystrophin deficiency in DMD results in mechanical deficits in striated muscle [5]. Respiratory 
muscle weakness occurs in DMD, with major implications for respiratory control [37]. Inspiratory 
muscle strength declines with increasing age in DMD boys [6]. Respiratory disturbances are common 
during sleep, including hypoventilation [38,39] and apnoeic events [37,40,41]. The mdx mouse model 
of DMD has characteristics similar to DMD, including disruptions to normal breathing [12,42–44] and 
diaphragm and pharyngeal dilator muscle weakness [12,15,16,32,45]. Adequate respiratory muscle 
function is essential for ventilation and mechanical manoeuvres including coughing and sneezing, 
mechanisms which safeguard against airway collapse. Given the clinical implications of poor 
respiratory system function in DMD, the development of new therapeutic strategies aimed at 
boosting respiratory muscle performance is essential. 
Herein, diaphragm muscle weakness in mdx mice was evidenced by reduced tetanic force, 
consistent with previous reports in young and older mdx mice [12–14,16,17]. Specific force was 
reduced within the frequency range of 40–160 Hz for mdx diaphragm compared with wild type. This 
frequency range corresponds to a broad range of ventilatory and non-ventilatory behaviours [13,46–
48]. Structural abnormalities occur in dystrophic muscle as a consequence of muscle fibre damage 
and degeneration. Our study confirmed structural alterations in mdx diaphragm, including a 
substantial increase in the number of centralized myonuclei (measure of fibre regeneration following 
damage), increased expression of MyHCEMB and increased collagen content (fibrosis). We observed a 
leftward shift in the frequency distribution of dystrophic muscle fibre size and a concomitant increase 
in the variability of fibre size. These observations are consistent with and extend our previous 
findings [12,17] and those of others [49,50], revealing substantial diaphragm muscle pathology in 
young (8 week old) mdx mice. 
Systemic and muscle inflammation are prominent features of DMD, secondary to muscle fibre 
damage. There is elevated expression of chemokines [51,52] and pro-inflammatory cytokines [53,54] 
in serum and muscle biopsies from DMD boys. In the current study, we report elevated pro-
inflammatory (IL-1β and IL-6) and anti-inflammatory (IL-10) cytokine concentrations in plasma 
samples from mdx mice. Immune cells are recruited to areas of damaged muscle, evidenced by 
increased immune cell infiltration in dystrophic muscle [55]. Here, we report an increase in putative 
inflammatory cells in mdx diaphragm. The concentrations of the pro-inflammatory cytokines, IL-1β 
and IL-6, and the chemokine KC/GRO are increased in mdx diaphragm. Anti-inflammatory drugs 
have been shown to have beneficial effects on mdx skeletal muscle form, but limited improvements 
in muscle force [55,56]. Encouragingly, however, blockade of pro-inflammatory cytokine signalling 
has proved beneficial to mdx respiratory muscle form and function [17,33,57,58]. 
Recent studies suggest a close relationship between oxidative stress and inflammation in 
dystrophic muscle pathology [4,21,59]. Oxidative stress develops as a consequence of increased 
generation of ROS and/or decreased endogenous antioxidant capacity. Immune cells in muscle can 
produce ROS [60], which at high levels can lead to impaired muscle force-generating capacity [19]. 
ROS are primarily produced by the mitochondria and enzyme complexes such as NADPH oxidase 
(NOX) and xanthine oxidase. Cellular damage occurs during periods of excessive ROS production. 
Muscle biopsies from DMD boys indicate increased levels of lipid peroxidation, an indirect measure 
of elevated ROS [61]. Expression of the ROS generating enzyme NOX2 is elevated in DMD muscle 
[4]. Endogenous antioxidant defence appears to be curtailed in DMD. For example, the activity of 
superoxide dismutase is decreased in DMD muscle [62]. Studies of the glutathione system in DMD 
boys suggests glutathione deficiency [63,64]. In DMD muscle biopsies, decreased antioxidant activity 
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confers reduced antioxidant defence increasing the risk of oxidative damage. Similarly, diaphragm 
muscle weakness in mdx mice is associated with altered redox balance [21,65]. ROS production is 
increased in mdx muscle [66,67]. NOX is elevated in mdx diaphragm and limb muscle [68–70]. Levels 
of 4-hydroxynonenal are elevated in mdx diaphragm, indicating increased lipid peroxidation [28]. 
Respiratory and limb muscle samples from mdx mice have decreased citrate synthase activity, 
suggesting reduced mitochondrial content [22,27]. Protein thiol oxidation and carbonyl content are 
increased in mdx diaphragm [71], further supporting redox modulation of dystrophic respiratory 
muscle. 
Our examination of diaphragm mRNA expression indicated an increase in mRNA expression 
related to muscle atrophy (MuRF1), regeneration (MyoD, myogenin), inflammation (NFκB), 
oxidative stress (NOX2) and mitophagy (PARK2) in mdx diaphragm, and a reduction in antioxidant 
(SOD1)-related mRNA expression compared with wild type. The transcription factor Nrf2 is 
considered a regulator of antioxidant proteins in response to oxidative injury or inflammation. Nrf2 
mRNA was increased in mdx diaphragm, consistent with studies of elevated Nrf2 in DMD muscle 
[4]. An upregulation of Nrf2 signalling in dystrophic muscle suggests a defensive antioxidant 
response. 
We investigated the effects of NAC supplementation in mdx mice on ventilation in conscious 
mice, and inspiratory pressure and respiratory (diaphragm and external intercostal) EMG activity in 
anaesthetized mice. In addition, we determined diaphragm muscle structure and force-generating 
capacity, diaphragm glutathione, diaphragm and plasma cytokine concentrations, and diaphragm 
mRNA expression. NAC is a free radical scavenger and a precursor of reduced glutathione (GSH), 
boosting synthesis of the endogenous antioxidant. We administered 1% NAC in the drinking water 
to mdx mice for 14 consecutive days beginning at 6 weeks of age. We have previously demonstrated 
the beneficial effects of NAC supplementation in rodent models of hypoxia-induced respiratory 
muscle weakness, where NAC improves respiratory muscle force-generating capacity and boosts 
endogenous cell survival signalling [24–26,72]. In addition to its effects on the glutathione system and 
its important role as a ROS scavenger, NAC is also a mucolytic agent and has been considered as a 
therapeutic agent in respiratory conditions such as chronic obstructive pulmonary disease [73]. 
Previously, NAC was shown to attenuate diaphragm muscle fatigue in humans [74]. 
In the current study, NAC supplementation increased diaphragm specific force in mdx mice 
across the frequency range of 60–160 Hz. Structural improvements following NAC included a 
reduction in diaphragm collagen content and a decrease in the infiltration of putative inflammatory 
cells. Total absolute muscle shortening and maximal shortening velocity were both improved in mdx 
diaphragm following NAC supplementation due to improvements in mdx muscle optimal length. 
This was likely mediated, at least in part, by the reduction in diaphragm collagen content following 
NAC, decreasing tissue stiffness. Recent studies of NAC administration in mdx mice demonstrated 
improved grip strength, increased EDL force output ex vivo, and reduced muscle inflammation and 
oxidative stress [27]. Whitehead et al. (2008) also reported increased EDL force and reduced muscle 
damage and inflammation following NAC intervention [30]. Furthermore, NAC reduced myosin 
protein thiol oxidation in mdx limb muscle [27]. Interestingly, NAC has been shown to prevent 
myofibre damage in mdx mice following exercise [29,75]. Anti-fibrotic actions of NAC have also been 
observed in animal models of disease. For example, NAC decreased TGFβ signalling in fibroblasts 
[76]; cardiac fibrosis was decreased by NAC in a mouse model of heart failure [77]; NAC decreased 
fibrosis in soleus muscle in a murine model of peripheral arterial insufficiency [78]; and renal fibrosis 
was decreased by NAC in a model of dilated cardiomyopathy [79]. 
We examined the glutathione system in the diaphragm of wild type, mdx and mdx + NAC mice. 
Glutathione is an endogenous antioxidant that exists in both a reduced (GSH) and oxidized (GSSG) 
state. Glutathione peroxidase (GPx) catalyses the oxidation reaction of GSH to GSSG, whereas 
glutathione reductase catalyses the reduction of GSSG to GSH. Glutathione reductase activity was 
increased in mdx diaphragm, along with a reduction in the GSSG:GSH ratio. These data suggest an 
early antioxidant defence, perhaps in response to a modest oxidative stress (buffered by glutathione 
reductase) in diaphragm from young mdx mice. 
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Given the close relationship between inflammation and oxidative stress, we examined immune 
cell infiltration in the diaphragm and the concentration of cytokines in diaphragm and plasma 
samples. Supplementation with NAC reduced the relative area of infiltrating inflammatory cells in 
mdx diaphragm. Cytokine concentrations were determined in plasma and diaphragm muscle 
samples following NAC administration. The pro-inflammatory cytokine IL-1β and the chemokine 
KC/GRO were reduced in mdx plasma samples following NAC. In addition, there was a sizeable 
reduction in plasma IL-6 levels (11 ± 18 versus 23 ± 25 pg.ml−1 plasma; mdx + NAC versus mdx). For 
diaphragm, sizeable reductions in the concentration of IL-1β (0.47 ± 0.17 versus 1.04 ± 0.62 pg.mg−1 
protein homogenate; mdx + NAC versus mdx), IL-6 (32 ± 21 versus 137 ± 155 pg.mg−1 protein 
homogenate) and KC/GRO (25 ± 17 versus 42 ± 23 pg.mg−1 protein homogenate) were observed 
following NAC. These data are in agreement with previous studies of NAC intervention in mdx mice. 
Pinniger et al. (2017) demonstrated that NAC supplementation reduced neutrophils and 
myeloperoxidase activity in mdx gastrocnemius muscle [27]. De Senzi Moraes Pinto et al. (2013) 
reported that NAC supplementation in young mdx mice reduced TNF-α protein expression [28]. 
Given the emerging benefits of reduced pro-inflammatory cytokine signalling in mdx respiratory 
muscle, these anti-inflammatory effects of NAC likely contributed to improved respiratory muscle 
performance in mdx mice. Our study suggests that the potential anti-inflammatory effects of NAC in 
dystrophic muscle warrant further attention. 
Breathing was assessed using whole-body plethysmography in conscious mice during baseline 
(21% O2) and chemoactivated breathing with hypercapnic-hypoxia (FiO2 = 0.10 and FiCO2 = 0.06). 
These assessments confirmed the capacity for mdx mice to enhance ventilation as previously 
described [12,13]. Tidal volume generation during hypercapnic-hypoxia was lower in mdx compared 
with wild type and was not rescued by NAC. In addition, we examined respiratory airflow and 
volume measures in anaesthetized mice following bilateral section of the vagi and with 
superimposed chemo-activation (FiO2 = 0.15 and FiCO2 = 0.06) to maximally activate ventilation. VT 
and inspiratory and expiratory flows were equivalent or greater in mdx mice compared with wild 
type revealing preserved ventilatory capacity in young mdx mice despite dystrophic disease. Direct 
measures of fR, VT and VE and peak inspiratory and expiratory flows were equivalent between mdx 
and mdx + NAC groups, revealing no adverse effect of NAC on respiratory airflow and volume in 
mdx mice. 
Our recent study reported lower diaphragm EMG activity in anaesthetized mdx mice during 
maximum activation [13]. Despite structural remodelling, profound weakness and lower EMG 
activity in mdx diaphragm, inspiratory pressure-generating capacity is remarkably preserved across 
ventilatory (chemoactivated breathing and augmented breaths) and non-ventilatory behaviours 
(sustained tracheal occlusion) [13], revealing a role for accessory and auxiliary muscles in support of 
peak inspiratory pressure generation in dystrophic disease [80]. We compared oesophageal pressure 
and respiratory muscle EMG (diaphragm and external intercostal) measurements in mdx mice 
following supplementation with 1% NAC to our previously published results. Values for 
oesophageal pressure during baseline (−9.3 ± 3.4 versus −9.2 ± 3.5 cmH2O; mdx + NAC versus mdx) and 
maximal inspiratory efforts (−55.4 ± 13.3 versus 59.7 ± 11.8 cmH2O; mdx + NAC versus mdx) were 
equivalent between mdx and mdx + NAC mice. Furthermore, NAC supplementation had no effect on 
diaphragm and external intercostal EMG activity in mdx mice during baseline conditions (diaphragm: 
6 ± 4 versus 6 ± 5 A.U.; EIC: 3 ± 1 versus 3 ± 2 A.U.; mdx + NAC versus mdx) and peak inspiratory efforts 
during airway obstruction (diaphragm: 30 ± 17 versus 25 ± 15 A.U.; EIC: 18 ± 13 versus 14 ± 9 A.U.; 
mdx + NAC versus mdx). Decreased maximal respiratory EMG activities in mdx mice is likely reflective 
of neuromuscular junction impairment [81,82], which appears not to have been affected by NAC 
administration, but this requires further investigation. 
Measures of somatic growth such as tibia length and mass were equivalent across all three 
groups. In terms of organ measures, mdx mice had heavier right and left heart ventricles and spleens 
than age-matched wild type mice. This is consistent with our previous observations [17,42]. Brown 
and white adipose tissues were decreased in mdx compared with wild type; NAC supplementation 
resulted in a modest increase in brown adipose tissue mass. Collectively, these are interesting 
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findings in the context of previous research addressing potential side effects of NAC particularly in 
respect of reductions in body mass [27,75,83]. Left ventricle mass was unaffected by NAC 
supplementation in mdx mice, while right ventricle mass was decreased. This could potentially be a 
beneficial effect of NAC acting to reduce cardiac muscle hypertrophy or collagen deposition in the 
right ventricle. Overall, NAC supplementation had no major effects on body mass, indices of somatic 
growth, organ mass and brown and white adipose tissue mass, demonstrating no adverse effects of 
our relatively short intervention. Changes in right ventricle and spleen mass were observed and it 
will be important to discern in future work if these changes are adaptive or maladaptive outcomes in 
dystrophic tissue in response to NAC. Future work should widen the scope of assessment of the 
effects of NAC supplementation on physiological systems and incorporate assessments of NAC in 
other animal models of muscular dystrophy. It will be important to establish the efficacy of NAC 
supplementation in models of advanced dystrophic disease affecting ventilatory performance. 
5. Conclusions 
In summary, mdx mice have diaphragm muscle weakness and myofibre remodelling, immune 
cell infiltration and collagen deposition. Pro-inflammatory cytokines are increased in diaphragm 
muscle and plasma samples from mdx mice. Supplementation of mdx mice with NAC resulted in 
functional improvements of the diaphragm muscle, immune cell infiltrates and collagen deposits 
were reduced in the diaphragm, and systemic cytokine concentrations were reduced and diaphragm 
Nrf2 mRNA expression was increased. There were also sizeable reductions in the concentrations of 
IL-1β and IL-6 in mdx diaphragms following NAC supplementation. These findings are important 
and relevant to the development of adjunctive therapies with an ambition to alleviate muscle 
pathology in human dystrophinopathies. 
Author Contributions: Conceptualization, D.P.B., D.E., K.D.O.; methodology, D.P.B., S.E.D., D.B., A.C., K.H.M., 
D.E., K.D.O.; formal analysis, D.P.B., S.E.D., D.B., A.C., K.H.M., D.E., K.D.O.; writing—original draft 
preparation, D.P.B., D.E., K.D.O.; writing—review and editing, K.D.O. 
Funding: Work carried out in TCD was supported by funding from the Department of Physiology, TCD and 
The Physiological Society. D.P.B., S.E.D. and K.H.M. were supported by funding from the Department of 
Physiology, UCC. 
Acknowledgments: We are grateful to staff of the Biological Services Unit, UCC for support with animal care 
and welfare. 
Conflicts of Interest: The authors declare no conflict of interest. 
References 
1. Yiu, E.M.; Kornberg, A.J. Duchenne muscular dystrophy. Neurol India 2008, 56, 236-247. 
2. Petrof, B.J.; Shrager, J.B.; Stedman, H.H.; Kelly, A.M.; Sweeney, H.L. Dystrophin protects the sarcolemma 
from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 1993, 90, 3710-3714. 
3. Ervasti, J.M.; Campbell, K.P. Membrane organization of the dystrophin-glycoprotein complex. Cell 1991, 
66, 1121-1131. 
4. Petrillo, S.; Pelosi, L.; Piemonte, F.; Travaglini, L.; Forcina, L.; Catteruccia, M.; Petrini, S.; Verardo, M.; 
D'Amico, A.; Musarò, A., et al. Oxidative stress in Duchenne muscular dystrophy: focus on the NRF2 redox 
pathway. Hum Mol Genet 2017, 26, 2781-2790, doi:10.1093/hmg/ddx173. 
5. Deconinck, N.; Dan, B. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr 
Neurol 2007, 36, 1-7, doi:10.1016/j.pediatrneurol.2006.09.016. 
6. Khirani, S.; Ramirez, A.; Aubertin, G.; Boulé, M.; Chemouny, C.; Forin, V.; Fauroux, B. Respiratory muscle 
decline in Duchenne muscular dystrophy. Pediatr Pulmonol 2014, 49, 473-481, doi:10.1002/ppul.22847. 
7. Mayer, O.H.; Finkel, R.S.; Rummey, C.; Benton, M.J.; Glanzman, A.M.; Flickinger, J.; Lindström, B.M.; 
Meier, T. Characterization of pulmonary function in Duchenne Muscular Dystrophy. Pediatr Pulmonol 2015, 
50, 487-494, doi:10.1002/ppul.23172. 
8. Meier, T.; Rummey, C.; Leinonen, M.; Spagnolo, P.; Mayer, O.H.; Buyse, G.M.; Group, D.S. Characterization 
of pulmonary function in 10-18 year old patients with Duchenne muscular dystrophy. Neuromuscul Disord 
2017, 27, 307-314, doi:10.1016/j.nmd.2016.12.014. 
Antioxidants 2019, 8, 581 23 of 26 
9. De Bruin, P.F.; Ueki, J.; Bush, A.; Khan, Y.; Watson, A.; Pride, N.B. Diaphragm thickness and inspiratory 
strength in patients with Duchenne muscular dystrophy. Thorax 1997, 52, 472-475. 
10. Barbé, F.; Quera-Salva, M.A.; McCann, C.; Gajdos, P.; Raphael, J.C.; de Lattre, J.; Agustí, A.G. Sleep-related 
respiratory disturbances in patients with Duchenne muscular dystrophy. Eur Respir J 1994, 7, 1403-1408. 
11. Toussaint, M.; Davidson, Z.; Bouvoie, V.; Evenepoel, N.; Haan, J.; Soudon, P. Dysphagia in Duchenne 
muscular dystrophy: practical recommendations to guide management. Disabil Rehabil 2016, 38, 2052-2062, 
doi:10.3109/09638288.2015.1111434. 
12. Burns, D.P.; Roy, A.; Lucking, E.F.; McDonald, F.B.; Gray, S.; Wilson, R.J.; Edge, D.; O'Halloran, K.D. 
Sensorimotor control of breathing in the mdx mouse model of Duchenne muscular dystrophy. J Physiol 
2017, 595, 6653-6672, doi:10.1113/JP274792. 
13. Burns, D.P.; Murphy, K.H.; Lucking, E.F.; O'Halloran, K.D. Inspiratory pressure-generating capacity is 
preserved during ventilatory and non-ventilatory behaviours in young dystrophic mdx mice despite 
profound diaphragm muscle weakness. J Physiol 2019, 597, 831-848, doi:10.1113/JP277443. 
14. Coirault, C.; Pignol, B.; Cooper, R.N.; Butler-Browne, G.; Chabrier, P.E.; Lecarpentier, Y. Severe muscle 
dysfunction precedes collagen tissue proliferation in mdx mouse diaphragm. J Appl Physiol (1985) 2003, 94, 
1744-1750, doi:10.1152/japplphysiol.00989.2002. 
15. Coirault, C.; Lambert, F.; Marchand-Adam, S.; Attal, P.; Chemla, D.; Lecarpentier, Y. Myosin molecular 
motor dysfunction in dystrophic mouse diaphragm. Am J Physiol 1999, 277, C1170-1176. 
16. Stedman, H.H.; Sweeney, H.L.; Shrager, J.B.; Maguire, H.C.; Panettieri, R.A.; Petrof, B.; Narusawa, M.; 
Leferovich, J.M.; Sladky, J.T.; Kelly, A.M. The mdx mouse diaphragm reproduces the degenerative changes 
of Duchenne muscular dystrophy. Nature 1991, 352, 536-539, doi:10.1038/352536a0. 
17. Burns, D.P.; Canavan, L.; Rowland, J.; O'Flaherty, R.; Brannock, M.; Drummond, S.E.; O'Malley, D.; Edge, 
D.; O'Halloran, K.D. Recovery of respiratory function in mdx mice co-treated with neutralizing interleukin-
6 receptor antibodies and urocortin-2. J Physiol 2018, 596, 5175-5197, doi:10.1113/JP276954. 
18. Moraes, L.H.; de Burgos, R.R.; Macedo, A.B.; de Almeida Hermes, T.; de Faria, F.M.; Minatel, E. Reduction 
of Oxidative Damage and Inflammatory Response in the Diaphragm Muscle of mdx Mice Using Iron 
Chelator Deferoxamine. Biol Trace Elem Res 2015, 167, 115-120, doi:10.1007/s12011-015-0290-y. 
19. Reid, M.B. Invited Review: redox modulation of skeletal muscle contraction: what we know and what we 
don't. J Appl Physiol 2001, 90, 724-731. 
20. O'Halloran, K.D.; Lewis, P. Respiratory muscle dysfunction in animal models of hypoxic disease: 
antioxidant therapy goes from strength to strength. Hypoxia (Auckl) 2017, 5, 75-84, doi:10.2147/HP.S141283. 
21. Lawler, J.M. Exacerbation of pathology by oxidative stress in respiratory and locomotor muscles with 
Duchenne muscular dystrophy. J Physiol 2011, 589, 2161-2170, doi:10.1113/jphysiol.2011.207456. 
22. Burns, D.P.; Ali, I.; Rieux, C.; Healy, J.; Jasionek, G.; O'Halloran, K.D. Tempol Supplementation Restores 
Diaphragm Force and Metabolic Enzyme Activities in mdx Mice. Antioxidants, 2017, 6, 101, 
doi:10.3390/antiox6040101. 
23. Hermes, T.A.; Mâncio, R.D.; Macedo, A.B.; Mizobuti, D.S.; Rocha, G.L.D.; Cagnon, V.H.A.; Minatel, E. 
Tempol treatment shows phenotype improvement in mdx mice. PLoS One 2019, 14, e0215590, 
doi:10.1371/journal.pone.0215590. 
24. O'Leary, A.J.; Drummond, S.E.; Edge, D.; O'Halloran, K.D. Diaphragm Muscle Weakness Following Acute 
Sustained Hypoxic Stress in the Mouse Is Prevented by Pretreatment with N-Acetyl Cysteine. Oxid Med 
Cell Longev 2018, 2018, 4805493, doi:10.1155/2018/4805493. 
25. Lewis, P.; Sheehan, D.; Soares, R.; Coelho, A.V.; O'Halloran, K.D. Redox Remodeling Is Pivotal in Murine 
Diaphragm Muscle Adaptation to Chronic Sustained Hypoxia. Am J Respir Cell Mol Biol 2016, 55, 12-23, 
doi:10.1165/rcmb.2015-0272OC. 
26. Shortt, C.M.; Fredsted, A.; Chow, H.B.; Williams, R.; Skelly, J.R.; Edge, D.; Bradford, A.; O'Halloran, K.D. 
Reactive oxygen species mediated diaphragm fatigue in a rat model of chronic intermittent hypoxia. Exp 
Physiol 2014, 99, 688-700, doi:10.1113/expphysiol.2013.076828. 
27. Pinniger, G.J.; Terrill, J.R.; Assan, E.B.; Grounds, M.D.; Arthur, P.G. Pre-clinical evaluation of N-
acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy. J Physiol 
2017, 595, 7093-7107, doi:10.1113/JP274229. 
28. de Senzi Moraes Pinto, R.; Ferretti, R.; Moraes, L.H.; Neto, H.S.; Marques, M.J.; Minatel, E. N-acetylcysteine 
treatment reduces TNF-α levels and myonecrosis in diaphragm muscle of mdx mice. Clin Nutr 2013, 32, 
472-475, doi:10.1016/j.clnu.2012.06.001. 
29. Terrill, J.R.; Radley-Crabb, H.G.; Grounds, M.D.; Arthur, P.G. N-Acetylcysteine treatment of dystrophic 
mdx mice results in protein thiol modifications and inhibition of exercise induced myofibre necrosis. 
Neuromuscul Disord 2012, 22, 427-434, doi:10.1016/j.nmd.2011.11.007. 
Antioxidants 2019, 8, 581 24 of 26 
30. Whitehead, N.P.; Pham, C.; Gervasio, O.L.; Allen, D.G. N-Acetylcysteine ameliorates skeletal muscle 
pathophysiology in mdx mice. J Physiol 2008, 586, 2003-2014, doi:10.1113/jphysiol.2007.148338. 
31. Grundy, D. Principles and standards for reporting animal experiments in The Journal of Physiology and 
Experimental Physiology. J Physiol 2015, 593, 2547-2549, doi:10.1113/JP270818. 
32. Burns, D.P.; O'Halloran, K.D. Evidence of hypoxic tolerance in weak upper airway muscle from young 
mdx mice. Respir Physiol Neurobiol 2016, 226, 68-75, doi:10.1016/j.resp.2015.12.001. 
33. Burns, D.P.; Rowland, J.; Canavan, L.; Murphy, K.H.; Brannock, M.; O'Malley, D.; O'Halloran, K.D.; Edge, 
D. Restoration of pharyngeal dilator muscle force in dystrophin-deficient (mdx) mice following co-
treatment with neutralizing interleukin-6 receptor antibodies and urocortin 2. Exp Physiol 2017, 102, 1177-
1193, doi:10.1113/EP086232. 
34. Lewis, P.; Sheehan, D.; Soares, R.; Varela Coelho, A.; O'Halloran, K.D. Chronic sustained hypoxia-induced 
redox remodeling causes contractile dysfunction in mouse sternohyoid muscle. Front Physiol 2015, 6, 122, 
doi:10.3389/fphys.2015.00122. 
35. Schiaffino, S.; Rossi, A.C.; Smerdu, V.; Leinwand, L.A.; Reggiani, C. Developmental myosins: expression 
patterns and functional significance. Skelet Muscle 2015, 5, 22, doi:10.1186/s13395-015-0046-6. 
36. Noirez, P.; Torres, S.; Cebrian, J.; Agbulut, O.; Peltzer, J.; Butler-Browne, G.; Daegelen, D.; Martelly, I.; 
Keller, A.; Ferry, A. TGF-beta1 favors the development of fast type identity during soleus muscle 
regeneration. J Muscle Res Cell Motil 2006, 27, 1-8, doi:10.1007/s10974-005-9014-9. 
37. LoMauro, A.; D'Angelo, M.G.; Aliverti, A. Sleep Disordered Breathing in Duchenne Muscular Dystrophy. 
Curr Neurol Neurosci Rep 2017, 17, 44, doi:10.1007/s11910-017-0750-1. 
38. Smith, P.E.; Edwards, R.H.; Calverley, P.M. Ventilation and breathing pattern during sleep in Duchenne 
muscular dystrophy. Chest 1989, 96, 1346-1351. 
39. Kirk, V.G.; Flemons, W.W.; Adams, C.; Rimmer, K.P.; Montgomery, M.D. Sleep-disordered breathing in 
Duchenne muscular dystrophy: a preliminary study of the role of portable monitoring. Pediatr Pulmonol 
2000, 29, 135-140. 
40. Khan, Y.; Heckmatt, J.Z. Obstructive apnoeas in Duchenne muscular dystrophy. Thorax 1994, 49, 157-161. 
41. Suresh, S.; Wales, P.; Dakin, C.; Harris, M.A.; Cooper, D.G. Sleep-related breathing disorder in Duchenne 
muscular dystrophy: disease spectrum in the paediatric population. J Paediatr Child Health 2005, 41, 500-
503, doi:10.1111/j.1440-1754.2005.00691.x. 
42. Burns, D.P.; Edge, D.; O'Malley, D.; O'Halloran, K.D. Respiratory Control in the mdx Mouse Model of 
Duchenne Muscular Dystrophy. Adv Exp Med Biol 2015, 860, 239-244, doi:10.1007/978-3-319-18440-1_27. 
43. Mosqueira, M.; Baby, S.M.; Lahiri, S.; Khurana, T.S. Ventilatory chemosensory drive is blunted in the mdx 
mouse model of Duchenne Muscular Dystrophy (DMD). PLoS One 2013, 8, e69567, 
doi:10.1371/journal.pone.0069567. 
44. Gayraud, J.; Matecki, S.; Hnia, K.; Mornet, D.; Prefaut, C.; Mercier, J.; Michel, A.; Ramonatxo, M. Ventilation 
during air breathing and in response to hypercapnia in 5 and 16 month-old mdx and C57 mice. J Muscle 
Res Cell Motil 2007, 28, 29-37, doi:10.1007/s10974-007-9101-1. 
45. Attal, P.; Lambert, F.; Marchand-Adam, S.; Bobin, S.; Pourny, J.C.; Chemla, D.; Lecarpentier, Y.; Coirault, 
C. Severe mechanical dysfunction in pharyngeal muscle from adult mdx mice. Am J Respir Crit Care Med 
2000, 162, 278-281. 
46. Sieck, G.C.; Ferreira, L.F.; Reid, M.B.; Mantilla, C.B. Mechanical properties of respiratory muscles. Compr 
Physiol 2013, 3, 1553-1567, doi:10.1002/cphy.c130003. 
47. Mantilla, C.B.; Seven, Y.B.; Sieck, G.C. Convergence of pattern generator outputs on a common mechanism 
of diaphragm motor unit recruitment. Prog Brain Res 2014, 209, 309-329, doi:10.1016/B978-0-444-63274-
6.00016-3. 
48. O'Halloran, K.D.; Burns, D.P. Breathing with neuromuscular disease: Does compensatory plasticity in the 
motor drive to breathe offer a potential therapeutic target in muscular dystrophy? Respir Physiol Neurobiol 
2019, 265, 49-54, doi:10.1016/j.resp.2018.06.009. 
49. Barros Maranhão, J.; de Oliveira Moreira, D.; Maurício, A.F.; de Carvalho, S.C.; Ferretti, R.; Pereira, J.A.; 
Santo Neto, H.; Marques, M.J. Changes in calsequestrin, TNF-α, TGF-β and MyoD levels during the 
progression of skeletal muscle dystrophy in mdx mice: a comparative analysis of the quadriceps, 
diaphragm and intrinsic laryngeal muscles. Int J Exp Pathol 2015, 96, 285-293, doi:10.1111/iep.12142. 
50. Gutpell, K.M.; Hrinivich, W.T.; Hoffman, L.M. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates 
its suitability as a murine model of Duchenne muscular dystrophy. PLoS One 2015, 10, e0117306, 
doi:10.1371/journal.pone.0117306. 
51. Pescatori, M.; Broccolini, A.; Minetti, C.; Bertini, E.; Bruno, C.; D'amico, A.; Bernardini, C.; Mirabella, M.; 
Silvestri, G.; Giglio, V., et al. Gene expression profiling in the early phases of DMD: a constant molecular 
Antioxidants 2019, 8, 581 25 of 26 
signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J 
2007, 21, 1210-1226, doi:10.1096/fj.06-7285com. 
52. De Paepe, B.; Creus, K.K.; Martin, J.J.; De Bleecker, J.L. Upregulation of chemokines and their receptors in 
Duchenne muscular dystrophy: potential for attenuation of myofiber necrosis. Muscle Nerve 2012, 46, 917-
925, doi:10.1002/mus.23481. 
53. Messina, S.; Vita, G.L.; Aguennouz, M.; Sframeli, M.; Romeo, S.; Rodolico, C.; Vita, G. Activation of NF-
kappaB pathway in Duchenne muscular dystrophy: relation to age. Acta Myol 2011, 30, 16-23. 
54. Cruz-Guzmán, O.e.R.; Rodríguez-Cruz, M.; Escobar Cedillo, R.E. Systemic Inflammation in Duchenne 
Muscular Dystrophy: Association with Muscle Function and Nutritional Status. Biomed Res Int 2015, 2015, 
891972, doi:10.1155/2015/891972. 
55. Eghtesad, S.; Jhunjhunwala, S.; Little, S.R.; Clemens, P.R. Rapamycin ameliorates dystrophic phenotype in 
mdx mouse skeletal muscle. Mol Med 2011, 17, 917-924, doi:10.2119/molmed.2010.00256. 
56. Serra, F.; Quarta, M.; Canato, M.; Toniolo, L.; De Arcangelis, V.; Trotta, A.; Spath, L.; Monaco, L.; Reggiani, 
C.; Naro, F. Inflammation in muscular dystrophy and the beneficial effects of non-steroidal anti-
inflammatory drugs. Muscle Nerve 2012, 46, 773-784, doi:10.1002/mus.23432. 
57. Pelosi, L.; Berardinelli, M.G.; De Pasquale, L.; Nicoletti, C.; D'Amico, A.; Carvello, F.; Moneta, G.M.; 
Catizone, A.; Bertini, E.; De Benedetti, F., et al. Functional and Morphological Improvement of Dystrophic 
Muscle by Interleukin 6 Receptor Blockade. EBioMedicine 2015, 2, 285-293, doi:10.1016/j.ebiom.2015.02.014. 
58. Manning, J.; Buckley, M.M.; O'Halloran, K.D.; O'Malley, D. Combined xIL-6R and urocortin-2 treatment 
restores mdx diaphragm muscle force. Muscle Nerve 2017, 56, E134-140, doi:10.1002/mus.25644. 
59. Pelosi, L.; Forcina, L.; Nicoletti, C.; Scicchitano, B.M.; Musarò, A. Increased Circulating Levels of 
Interleukin-6 Induce Perturbation in Redox-Regulated Signaling Cascades in Muscle of Dystrophic Mice. 
Oxid Med Cell Longev 2017, 2017, 1987218, doi:10.1155/2017/1987218. 
60. Tidball, J.G. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 
2005, 288, R345-353, doi:10.1152/ajpregu.00454.2004. 
61. Mechler, F.; Imre, S.; Dioszeghy, P. Lipid peroxidation and superoxide dismutase activity in muscle and 
erythrocytes in Duchenne muscular dystrophy. J Neurol Sci 1984, 63, 279-283. 
62. Burr, I.M.; Asayama, K.; Fenichel, G.M. Superoxide dismutases, glutathione peroxidase, and catalase in 
neuromuscular disease. Muscle Nerve 1987, 10, 150-154, doi:10.1002/mus.880100208. 
63. Khouzami, L.; Bourin, M.C.; Christov, C.; Damy, T.; Escoubet, B.; Caramelle, P.; Perier, M.; Wahbi, K.; 
Meune, C.; Pavoine, C., et al. Delayed cardiomyopathy in dystrophin deficient mdx mice relies on intrinsic 
glutathione resource. Am J Pathol 2010, 177, 1356-1364, doi:10.2353/ajpath.2010.090479. 
64. Renjini, R.; Gayathri, N.; Nalini, A.; Srinivas Bharath, M.M. Oxidative damage in muscular dystrophy 
correlates with the severity of the pathology: role of glutathione metabolism. Neurochem Res 2012, 37, 885-
898, doi:10.1007/s11064-011-0683-z. 
65. Kim, J.H.; Kwak, H.B.; Thompson, L.V.; Lawler, J.M. Contribution of oxidative stress to pathology in 
diaphragm and limb muscles with Duchenne muscular dystrophy. J Muscle Res Cell Motil 2013, 34, 1-13, 
doi:10.1007/s10974-012-9330-9. 
66. Dudley, R.W.; Danialou, G.; Govindaraju, K.; Lands, L.; Eidelman, D.E.; Petrof, B.J. Sarcolemmal damage 
in dystrophin deficiency is modulated by synergistic interactions between mechanical and 
oxidative/nitrosative stresses. Am J Pathol 2006, 168, 1276-1287, doi:10.2353/ajpath.2006.050683. 
67. Whitehead, N.P.; Yeung, E.W.; Allen, D.G. Muscle damage in mdx (dystrophic) mice: role of calcium and 
reactive oxygen species. Clin Exp Pharmacol Physiol 2006, 33, 657-662, doi:10.1111/j.1440-1681.2006.04394.x. 
68. Whitehead, N.P.; Yeung, E.W.; Froehner, S.C.; Allen, D.G. Skeletal muscle NADPH oxidase is increased 
and triggers stretch-induced damage in the mdx mouse. PLoS One 2010, 5, e15354, 
doi:10.1371/journal.pone.0015354. 
69. Loehr, J.A.; Wang, S.; Cully, T.R.; Pal, R.; Larina, I.V.; Larin, K.V.; Rodney, G.G. NADPH oxidase mediates 
microtubule alterations and diaphragm dysfunction in dystrophic mice. eLife 2018, 7, e31732, 
doi:10.7554/eLife.31732. 
70. Whitehead, N.P.; Kim, M.J.; Bible, K.L.; Adams, M.E.; Froehner, S.C. A new therapeutic effect of simvastatin 
revealed by functional improvement in muscular dystrophy. Proc Natl Acad Sci U S A 2015, 112, 12864-
12869, doi:10.1073/pnas.1509536112. 
71. El-Shafey, A.F.; Armstrong, A.E.; Terrill, J.R.; Grounds, M.D.; Arthur, P.G. Screening for increased protein 
thiol oxidation in oxidatively stressed muscle tissue. Free Radic Res 2011, 45, 991-999, 
doi:10.3109/10715762.2011.590136. 
72. Dunleavy, M.; Bradford, A.; O'Halloran, K.D. Oxidative stress impairs upper airway muscle endurance in 
an animal model of sleep-disordered breathing. Adv Exp Med Biol 2008, 605, 458-462, doi:10.1007/978-0-387-
73693-8_80. 
Antioxidants 2019, 8, 581 26 of 26 
73. Sadowska, A.M.; Verbraecken, J.; Darquennes, K.; De Backer, W.A. Role of N-acetylcysteine in the 
management of COPD. Int J Chron Obstruct Pulmon Dis 2006, 1, 425-434. 
74. Travaline, J.M.; Sudarshan, S.; Roy, B.G.; Cordova, F.; Leyenson, V.; Criner, G.J. Effect of N-acetylcysteine 
on human diaphragm strength and fatigability. Am J Respir Crit Care Med 1997, 156, 1567-1571, 
doi:10.1164/ajrccm.156.5.96-09133. 
75. O'Halloran, K.D.; Murphy, K.H.; Burns, D.P. Antioxidant therapy for muscular dystrophy: caveat lector! J 
Physiol 2018, 596, 737-738, doi:10.1113/JP275598. 
76. Kopp, J.; Seyhan, H.; Müller, B.; Lanczak, J.; Pausch, E.; Gressner, A.M.; Dooley, S.; Horch, R.E. N-acetyl-L-
cysteine abrogates fibrogenic properties of fibroblasts isolated from Dupuytren's disease by blunting TGF-
beta signalling. J Cell Mol Med 2006, 10, 157-165. 
77. Giam, B.; Chu, P.Y.; Kuruppu, S.; Smith, A.I.; Horlock, D.; Kiriazis, H.; Du, X.J.; Kaye, D.M.; Rajapakse, 
N.W. N-acetylcysteine attenuates the development of cardiac fibrosis and remodeling in a mouse model of 
heart failure. Physiol Rep 2016, 4, e12757, doi:10.14814/phy2.12757. 
78. Roseguini, B.T.; Silva, L.M.; Polotow, T.G.; Barros, M.P.; Souccar, C.; Han, S.W. Effects of N-acetylcysteine 
on skeletal muscle structure and function in a mouse model of peripheral arterial insufficiency. J Vasc Surg 
2015, 61, 777-786, doi:10.1016/j.jvs.2013.10.098. 
79. Giam, B.; Kuruppu, S.; Chu, P.Y.; Smith, A.I.; Marques, F.Z.; Fiedler, A.; Horlock, D.; Kiriazis, H.; Du, X.J.; 
Kaye, D.M., et al. N-Acetylcysteine Attenuates the Development of Renal Fibrosis in Transgenic Mice with 
Dilated Cardiomyopathy. Sci Rep 2017, 7, 17718, doi:10.1038/s41598-017-17927-5. 
80. Burns, D.P.; Lucking, E.F.; O'Halloran, K.D. Reply from David P. Burns, Eric F. Lucking and Ken D. 
O'Halloran: Auxiliary compensation for diaphragm dysfunction in dystrophic disease. J Physiol 2019, 597, 
4103-4105, doi:10.1113/JP278371. 
81. Pratt, S.J.; Valencia, A.P.; Le, G.K.; Shah, S.B.; Lovering, R.M. Pre- and postsynaptic changes in the 
neuromuscular junction in dystrophic mice. Front Physiol 2015, 6, 252, doi:10.3389/fphys.2015.00252. 
82. van der Pijl, E.M.; van Putten, M.; Niks, E.H.; Verschuuren, J.J.; Aartsma-Rus, A.; Plomp, J.J. 
Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular 
dystrophy mouse models. Eur J Neurosci 2016, 43, 1623-1635, doi:10.1111/ejn.13249. 
83. Head, S.I. Antioxidant therapy in a mouse model of Duchenne muscular dystrophy: some promising 
results but with a weighty caveat. J Physiol 2017, 595, 7015, doi:10.1113/JP275232. 
 
©  2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
